Nafamostat has been used in clinical settings for the prevention and treatment of thrombosis, disseminated intravascular coagulation (DIC), and acute pancreatitis. It has also been investigated as a potential treatment for COVID-19, as it has been shown to inhibit the replication of SARS-CoV-2 in vitro.
Common side effects of nafamostat include bleeding, allergic reactions, and gastrointestinal symptoms such as nausea and vomiting. It should be used with caution in patients with bleeding disorders or liver or kidney dysfunction.
Nafamostat is available in various forms, including injection, powder, and tablet. It is typically administered by injection or infusion, and the dosage and duration of treatment may vary depending on the condition being treated and the patient’s individual needs. As with any medication, it is important to follow the prescribing doctor’s instructions and to report any side effects or concerns.
